|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...2829303132333435363738...6566» |
- Enrollment change, Trial withdrawal: Ampicillin-sulbactam Resistant E.Coli at UPMC (clinicaltrials.gov) - Dec 9, 2014
P=N/A, N=0, Withdrawn, Sponsor: University of Pittsburgh
N=300 --> 0 | Active, not recruiting --> Withdrawn
- azithromycin / Generic mfg.
Phase classification: RESCUE-L: Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) - Dec 9, 2014
P4, N=20, Enrolling by invitation, Sponsor: Pfizer
N=300 --> 0 | Active, not recruiting --> Withdrawn Phase classification: P=N/A --> P4
- |||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment open: Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902) (clinicaltrials.gov) - Dec 9, 2014
P4, N=240, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P=N/A --> P4 Not yet recruiting --> Recruiting
- || Mycobutin (rifabutin) / Pfizer, Lupin
Phase classification, Trial primary completion date: Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients (clinicaltrials.gov) - Dec 9, 2014
P4, N=500, Enrolling by invitation, Sponsor: Pfizer
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P4 | Trial primary completion date: Sep 2014 --> Dec 2014
- Clinical: Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients (clinicaltrials.gov) - Dec 8, 2014
P=N/A, N=114, Completed, Sponsor: Domonkos Trásy
- HEOR: PIVVOT: Comparative Effectiveness of Intravenous v. Oral Antibiotic Therapy for Serious Bacterial Infections (clinicaltrials.gov) - Dec 8, 2014
P=N/A, N=15000, Completed, Sponsor: Children's Hospital of Philadelphia
- aspirin / Generic mfg.
Trial primary completion date: Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding (clinicaltrials.gov) - Dec 7, 2014
P=N/A, N=904, Completed, Sponsor: Chinese University of Hong Kong
Phase classification: P=N/A --> P4 | Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: Jun 2010 --> Feb 2013
- || Altabax (retapamulin) / GSK, Almirall
Trial primary completion date: Retapamulin for Reducing MRSA Nasal Carriage (clinicaltrials.gov) - Dec 7, 2014
P4, N=150, Recruiting, Sponsor: University of California, Irvine
Trial primary completion date: Jun 2010 --> Feb 2013 Trial primary completion date: Dec 2014 --> Sep 2015
- Trial primary completion date: Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=900, Recruiting, Sponsor: Fundación Pública Andaluza Progreso y Salud
Trial primary completion date: Dec 2014 --> Sep 2015 Trial primary completion date: Jun 2014 --> Dec 2014
- || Trial primary completion date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=361, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: Jun 2014 --> Dec 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- |||||||||| New P3 trial: Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ. (clinicaltrials.gov) - Dec 6, 2014
P3, N=55, Not yet recruiting, Sponsor: Novartis
- Enrollment open, Trial initiation date, Trial primary completion date: Simplified GBS Screening and Prevalence of ESBL in Pregnant Women (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=480, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Sep 2015 --> Dec 2015
- Cubicin (daptomycin) / Merck (MSD)
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=6, Completed, Sponsor: University of Oklahoma
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Completed | N=10 --> 6 | Initiation date: Apr 2010 --> Nov 2009 | Trial primary completion date: Apr 2013 --> Apr 2014
- Trial primary completion date, Surgery: Fluorometholone as Ancillary Therapy for TT Surgery (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=156, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Completed | N=10 --> 6 | Initiation date: Apr 2010 --> Nov 2009 | Trial primary completion date: Apr 2013 --> Apr 2014 Trial primary completion date: Apr 2015 --> Apr 2016
- || Trial primary completion date: Safer Sex Program for Young African-American Men (clinicaltrials.gov) - Dec 6, 2014
P2, N=620, Recruiting, Sponsor: University of Kentucky
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: May 2017 --> May 2018
- afabicin IV (Debio 1450 IV) / Debiopharm, afabicin oral (Debio 1450) / Debiopharm
Clinical: A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers (clinicaltrials.gov) - Dec 6, 2014
P1, N=60, Recruiting, Sponsor: Debiopharm International SA
Trial primary completion date: May 2017 --> May 2018 Suspended --> Recruiting | N=40 --> 60 | Trial primary completion date: Nov 2014 --> Feb 2015
- Trial primary completion date: LAMRCT: A Trial of the Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=2400, Recruiting, Sponsor: University of Cape Town
Suspended --> Recruiting | N=40 --> 60 | Trial primary completion date: Nov 2014 --> Feb 2015 Trial primary completion date: Apr 2014 --> Dec 2014
- || vancomycin / Generic mfg.
Trial primary completion date: Bacteremia: Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection (clinicaltrials.gov) - Dec 5, 2014
P2, N=500, Recruiting, Sponsor: Duke University
Trial primary completion date: Apr 2014 --> Dec 2014 Trial primary completion date: Apr 2015 --> Jun 2016
- Clinical: MALDITOF Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=1000, Recruiting, Sponsor: Oxford University Clinical Research Unit, Vietnam
- zoliflodacin (ETX0914) / Entasis Therap, Global Antibiotic Research and Development Partnership
Enrollment open: Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea (clinicaltrials.gov) - Dec 5, 2014
P2, N=180, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Apr 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- |||||| Enrollment open: Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children (clinicaltrials.gov) - Dec 5, 2014
P3, N=660, Recruiting, Sponsor: Novartis
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Infant Antibiotic Resistance and Implications for Therapeutic Decision-making (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=300, Recruiting, Sponsor: University Hospital Case Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Trial completion: Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (clinicaltrials.gov) - Dec 5, 2014
P2, N=525, Completed, Sponsor: JN-International Medical Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Trial completion: A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults (clinicaltrials.gov) - Dec 5, 2014
P3, N=18, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cefixime / Generic mfg.
Trial primary completion date: The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study (clinicaltrials.gov) - Dec 5, 2014
P1, N=30, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Feb 2015
- levofloxacin / Generic mfg., cloxacillin / Generic mfg.
Trial primary completion date: Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus. (clinicaltrials.gov) - Dec 5, 2014
P3, N=154, Recruiting, Sponsor: Fundaci
Trial primary completion date: Aug 2014 --> Feb 2015 Trial primary completion date: Jun 2014 --> Jan 2015
- nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial primary completion date: DATiC: Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) (clinicaltrials.gov) - Dec 5, 2014
P4, N=240, Recruiting, Sponsor: University of Cape Town
Trial primary completion date: Jun 2014 --> Jan 2015 Trial primary completion date: Feb 2014 --> Feb 2015
- aspirin / Generic mfg.
Enrollment open: A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis (clinicaltrials.gov) - Dec 5, 2014
P2, N=120, Recruiting, Sponsor: Oxford University Clinical Research Unit, Vietnam
Trial primary completion date: Feb 2014 --> Feb 2015 Not yet recruiting --> Recruiting
- ceftriaxone / Generic mfg., azithromycin / Generic mfg.
Enrollment closed, Trial primary completion date, IO biomarker: Chlamydia Trachomatis Immunology and Vaccinology Study (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=350, Active, not recruiting, Sponsor: Harold Wiesenfeld
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Aug 2015
- ||| Trial completion, Enrollment change, Trial primary completion date: Gonorrhea and Chlamydia HIV-infected Men Who Have Sex With Men (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=150, Completed, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Aug 2015 Not yet recruiting --> Completed | N=300 --> 150 | Trial primary completion date: Jun 2014 --> Oct 2014
- || Trumenba (meningococcal B vaccine) / Pfizer
Trial primary completion date: A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents (clinicaltrials.gov) - Nov 28, 2014
P2, N=538, Completed, Sponsor: Pfizer
Not yet recruiting --> Completed | N=300 --> 150 | Trial primary completion date: Jun 2014 --> Oct 2014 Trial primary completion date: Oct 2010 --> Mar 2014
- Trumenba (meningococcal B vaccine) / Pfizer
Phase classification, Trial primary completion date: Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants (clinicaltrials.gov) - Nov 28, 2014
P2, N=46, Terminated, Sponsor: Pfizer
Trial primary completion date: Oct 2010 --> Mar 2014 Phase classification: P1/2 --> P2 | Trial primary completion date: Jan 2011 --> Jun 2009
- ||| Enrollment open: LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study (clinicaltrials.gov) - Nov 25, 2014
P0, N=60, Recruiting, Sponsor: CDA Research Group, Inc.
Phase classification: P1/2 --> P2 | Trial primary completion date: Jan 2011 --> Jun 2009 Suspended --> Recruiting
- |||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
Trial primary completion date: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (clinicaltrials.gov) - Nov 24, 2014
P3, N=750, Recruiting, Sponsor: Novartis
Suspended --> Recruiting Trial primary completion date: Jul 2015 --> Feb 2016
- Trial completion: POPI: Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=2531, Completed, Sponsor: St George's, University of London
Trial primary completion date: Jul 2015 --> Feb 2016 Active, not recruiting --> Completed
- ||||| Enrollment change: Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. (clinicaltrials.gov) - Nov 24, 2014
P3, N=240, Recruiting, Sponsor: Novartis
Active, not recruiting --> Completed N=150 --> 240
- Clinical: Early Procalcitonin Kinetics During Empirical Antibiotic Therapy in Critically Ill Patients (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=209, Completed, Sponsor: Domonkos Trásy
- ||||| gepotidacin (GSK2140944) / GSK
New P2 trial: A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae (clinicaltrials.gov) - Nov 19, 2014
P2, N=100, Not yet recruiting, Sponsor: GlaxoSmithKline
- | Enrollment closed, Trial primary completion date, Combination therapy: TESEC-07: Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses (clinicaltrials.gov) - Nov 19, 2014
P2/3, N=450, Active, not recruiting, Sponsor: Statens Serum Institut
N=150 --> 240 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015
- | Enrollment closed, Trial primary completion date, Combination therapy: A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI (clinicaltrials.gov) - Nov 19, 2014
P3, N=1175, Active, not recruiting, Sponsor: Statens Serum Institut
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Mar 2015
- | Enrollment closed, Trial primary completion date, Combination therapy: Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI (clinicaltrials.gov) - Nov 19, 2014
P3, N=950, Active, not recruiting, Sponsor: Statens Serum Institut
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Mar 2015
- Trial completion: Hospital Wide Roll-Out of Antimicrobial Stewardship (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=19220, Completed, Sponsor: Sunnybrook Health Sciences Centre
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Mar 2015 Recruiting --> Completed
- SQ-109 / Sequella
Trial primary completion date: Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers (clinicaltrials.gov) - Nov 18, 2014
P2a, N=30, Suspended, Sponsor: Sequella, Inc.
Recruiting --> Completed Trial primary completion date: Aug 2013 --> Aug 2015
- clindamycin phosphate / Generic mfg.
Enrollment closed, Enrollment change: CLIN01: Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile (clinicaltrials.gov) - Nov 18, 2014
P1, N=22, Active, not recruiting, Sponsor: Phillip Brian Smith
Trial primary completion date: Aug 2013 --> Aug 2015 Recruiting --> Active, not recruiting | N=32 --> 22
- |||| AMG 108 / AstraZeneca
Trial completion, Enrollment change: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Nov 18, 2014
P2a, N=224, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | N=32 --> 22 Active, not recruiting --> Completed | N=100 --> 224
- Trial completion, Enrollment change, Trial primary completion date, Nontuberculous mycobacteria: Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=150, Completed, Sponsor: University of Illinois at Chicago
Active, not recruiting --> Completed | N=100 --> 224 Recruiting --> Completed | N=1000 --> 150 | Trial primary completion date: Aug 2014 --> Nov 2014
- || Trial primary completion date: Characterizing and Comparing the Profile of Microorganisms From Specific Body Sites and Environmental Surfaces in Newly Disinfected Patient Rooms (clinicaltrials.gov) - Nov 17, 2014
P=N/A, N=80, Recruiting, Sponsor: Duke University
Recruiting --> Completed | N=1000 --> 150 | Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: Mar 2014 --> Dec 2014
- ||| Enrollment open, Pneumococcal vaccines: System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts (clinicaltrials.gov) - Nov 16, 2014
P=N/A, N=30000, Enrolling by invitation, Sponsor: University of Massachusetts, Worcester
Trial primary completion date: Mar 2014 --> Dec 2014 Not yet recruiting --> Enrolling by invitation
- ||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
Enrollment closed: Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea (clinicaltrials.gov) - Nov 14, 2014
P3, N=757, Active, not recruiting, Sponsor: Melinta Therapeutics, Inc.
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- ||| Enrollment closed, Trial primary completion date: STAR-Too: Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) (clinicaltrials.gov) - Nov 14, 2014
P2, N=80, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015